Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach.
Unlike conventional antidepressants, rolipram stimulates both the presynaptic as well as the postsynaptic component of monoaminergic transmission. Several double-blind comparative trials are on the way to assess the clinical efficacy and safety of this novel compound. The present study was a randomized double-blind double-dummy comparison with imipramine in inpatients with major, "minor" and atypical depressions (DSM III). Results show no relevant differences between rolipram and imipramine regarding efficacy and safety.
Bertolino
A
A
Psychiatric Hospital Bisceglie, University of Bari, Italy.
Crippa
D
D
di Dio
S
S
Fichte
K
K
Musmeci
G
G
Porro
V
V
Rapisarda
V
V
Sastre-y-Hernández
M
M
Schratzer
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011760:Pyrrolidinones / Q000627:therapeutic use*; D020889:Rolipram
D000928:Antidepressive Agents; D011760:Pyrrolidinones; D020889:Rolipram; D007099:Imipramine